ProTgen (Drug Discovery) Overview

  • Year Founded
  • 2023

Year Founded

  • Status
  • Private

  • Employees
  • 7

Employees

  • Latest Deal Type
  • Early Stage VC

  • Latest Deal Amount
  • $20M

  • Investors
  • 3

ProTgen (Drug Discovery) General Information

Description

Operator of a biotechnology company intended to support genetic engineering and protein production research. The company offers tools and services for gene design, protein expression, and molecular biology applications, enabling clients to develop and study engineered proteins and genetic constructs for research and biotechnology use.

Contact Information

Website
www.protgen.bio
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 224 King Street West
  • Suite 3902
  • Toronto, Ontario M5H 0A6
  • Canada
+1 (647)
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Vertical(s)
Corporate Office
  • 224 King Street West
  • Suite 3902
  • Toronto, Ontario M5H 0A6
  • Canada
+1 (647)

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

ProTgen (Drug Discovery) Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
1. Early Stage VC 02-Dec-2024 $20M Completed Pre-Clinical Trials
To view ProTgen (Drug Discovery)’s complete valuation and funding history, request access »

ProTgen (Drug Discovery) Patents

ProTgen (Drug Discovery) Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2026226777-A1 Multispecific ligands and uses thereof Pending 23-Apr-2025

ProTgen (Drug Discovery) Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

ProTgen (Drug Discovery) Investors (3)

Investor Name Investor Type Holding Investor Since Participating Rounds
Boehringer Ingelheim Venture Fund Corporate Venture Capital Minority
Eisai Innovation Corporate Venture Capital Minority
FACIT Venture Capital Minority
To view ProTgen (Drug Discovery)’s complete investors history, request access »

ProTgen (Drug Discovery) FAQs

  • When was ProTgen (Drug Discovery) founded?

    ProTgen (Drug Discovery) was founded in 2023.

  • Where is ProTgen (Drug Discovery) headquartered?

    ProTgen (Drug Discovery) is headquartered in Toronto, Canada.

  • What is the size of ProTgen (Drug Discovery)?

    ProTgen (Drug Discovery) has 7 total employees.

  • What industry is ProTgen (Drug Discovery) in?

    ProTgen (Drug Discovery)’s primary industry is Drug Discovery.

  • Is ProTgen (Drug Discovery) a private or public company?

    ProTgen (Drug Discovery) is a Private company.

  • What is ProTgen (Drug Discovery)’s current revenue?

    The current revenue for ProTgen (Drug Discovery) is .

  • How much funding has ProTgen (Drug Discovery) raised over time?

    ProTgen (Drug Discovery) has raised $20M.

  • Who are ProTgen (Drug Discovery)’s investors?

    Boehringer Ingelheim Venture Fund, Eisai Innovation, and FACIT have invested in ProTgen (Drug Discovery).

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process